Evolus expands Estyme HA gel rights to Canada, Australia, New Zealand; expects 2028 launch

Evolus, Inc.

Upfront payment of €920,000 plus up to €1.38 million upon regulatory approvals.
Estyme complements Jeuveau/Nuceiva; combined neurotoxin & filler TAM ~$500M annually.
Commercialization expected in 2028, subject to applicable regulatory approvals.
Symatese responsible for development, manufacturing, and regulatory; Evolus pays mid-single digit royalty.
Agreement expected to be accretive to Evolus' international gross margins.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.